Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10562044
Filing Date		2005-12-23
First Named Inventor	Dr. Bi	ill Cope
Art Unit		
Examiner Name		
Attorney Docket Number	or	90227

				Attorn	ey Doc	ket Number	902	27				
					11.6	PATENTS				Remove		
	_			_	0.3.	AIENIS			_	Homovo		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear					
	1											
If you wis	h to a	l dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add bu	utton.	_	Add		_
			U.S.P	ATENT	APPLI	CATION PUBL	ICATI	ONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva	ages,Columns,Lines where elevant Passages or Relevant igures Appear			
	1											
If you wisl	h to a	dd additional U.S. Publi		p		, ,		click the Ad	d button			
				FOREIG	SN PAT	ENT DOCUM	ENTS			Remove		
Examiner Cite Initial* No		Foreign Document Number ³		Country Kind Code ² i Cod		Publication Date		of Patente cant of cited ment	e or	where Rel	or Relevant	+=
	1	2223953	CA			1999-06-05	North Limite	em Telecom ed				
	2	2411459	CA			2003-05-12	NTT	Docomo, Inc.				
If you wisi	h to a	l dd additional Foreign P	atent Do	cument	citation	information ple	ease c	lick the Add	button	Add		_

	Application Number		10562044
INFORMATION DIGGS COURT	Filing Date		2005-12-23
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Dr. B	ill Cope
(Not for submission under 37 CFR 1.99)	Art Unit		
(······	Examiner Name		
	Attorney Docket Numb	er	90227

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher	T5	
	1	HERNANDEZ et al., "Clio: A Semi-Automatic Tool for Schema Mapping," article, [online], [retrieved on 2004-11-04], Retrieved from the CiteSeer IST website using internet <url 845976.html="" citeseer.ist.psu.edu="" http:=""></url>		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature | Date Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTIO Patent Documents at year USPTIO_CODY or MPEP 901.04. ² Either office that issued the document, by the bro-bitter code (WIPO Standard ST.3). ² Sort planence patent colouments, be excluded into one lever or the reign of the Emperor most procedule the serior immerror of the process of the colouments and of the colouments are considered to make or the coloument of the coloument by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ³ Applicant is to place a check mark here if English tanguage the relation is attached.

Attorney Docket Number 9

Please see 37	CFR 1.97 ar	nd 1.98 to mak	e the appropriate	selection(s):	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eV1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart to reign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 159(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jacqueline E. Hartt/	Date (YYYY-MM-DD)	2006-09-22
Name/Print	Jacqueline E. Hartt. Ph.D.	Registration Number	37845

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1436, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.